Azzad Asset Management Inc. ADV Acquires Shares of 14,876 Danaher Corporation (NYSE:DHR)

Azzad Asset Management Inc. ADV purchased a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 14,876 shares of the conglomerate's stock, valued at approximately $3,049,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Spinnaker Trust raised its holdings in shares of Danaher by 1.2% during the 4th quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate's stock valued at $988,000 after purchasing an additional 50 shares in the last quarter. Fortis Capital Advisors LLC lifted its position in shares of Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after buying an additional 50 shares during the last quarter. Fayez Sarofim & Co boosted its stake in shares of Danaher by 0.6% during the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after acquiring an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC increased its holdings in shares of Danaher by 4.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after acquiring an additional 50 shares during the last quarter. Finally, Perennial Investment Advisors LLC raised its stake in shares of Danaher by 2.2% in the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after acquiring an additional 51 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Price Performance

Shares of Danaher stock traded down $5.30 during trading on Tuesday, hitting $195.81. 2,968,631 shares of the company's stock traded hands, compared to its average volume of 3,487,825. The company has a market cap of $140.13 billion, a PE ratio of 38.02, a PEG ratio of 2.82 and a beta of 0.77. The firm's fifty day moving average price is $193.42 and its 200 day moving average price is $210.43. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.65%. Danaher's dividend payout ratio (DPR) is 24.85%.

Wall Street Analyst Weigh In

Several equities analysts have commented on DHR shares. TD Cowen increased their price target on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a report on Wednesday, April 23rd. The Goldman Sachs Group dropped their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Evercore ISI decreased their price target on shares of Danaher from $240.00 to $230.00 and set an "outperform" rating for the company in a report on Tuesday, April 22nd. Robert W. Baird dropped their price objective on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and a consensus price target of $248.17.

Insiders Place Their Bets

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.20% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.